Abstract 1851P
Background
We have previously reported on the initial results of the prospective longitudinal PICO-SM study (Lim et al. 2023), highlighting the impact of the COVID-19 pandemic on the lives of patients with colorectal cancer. Herein, we present the psychological impact of the third wave of the pandemic to patients, when the Omicron variant became prevalent (December 2021 to early 2022).
Methods
Patients were invited to participate in cohort II of the PICO-SM study by completing a questionnaire, including screening psychometric tools. Multivariate analysis was performed using logistic regression for binary outcomes: anxiety (GAD-7 score ≥ 5), depression (PHQ-9 score ≥ 10), and poor well-being (WHO-5 < 50); and odds ratios (OR) with 95% confidence interval (CI) were calculated.
Results
In total, 96 participants were included: mean age 64 years, 64% (n = 61) males. 33% (n = 32/96) reported poor well-being (WHO-5 < 50), 27% (n = 26/96) anxiety (GAD-7 ≥ 5), 11% (n = 11/96) depressive symptoms (PHQ-9 ≥ 10) and 3% (n = 3/96) probable post-traumatic stress disorder (PC-PTSD-5 ≥ 4). The results compare with distress levels in the second pandemic wave: 31%, 24%, 15% and 3%, respectively. Multivariate analysis showed that patients who had investigations cancelled (OR 9.22, 95% CI 1.09-77.85; p = 0.041) or felt that the pandemic would affect their mental health (OR 3.82, 95% CI 1.96-7.44; p < 0.001) had increased risk of anxiety. Similarly, concern that the pandemic would affect their cancer treatment (OR 4.59, 95% CI 1.03-20.56; p = 0.046) or would affect their mental health (OR 3.90, 95% CI 1.38-11.03; p = 0.010) were found independent predictors of poor wellbeing.
Conclusions
The psychological distress experienced by patients, particularly anxiety, remained persistently high during the third wave of the COVID-19 pandemic. These updated results align with our initial findings, emphasizing the critical importance of continuing cancer treatment amidst the ongoing humanitarian emergency. It is crucial for healthcare services to prioritize ongoing psychological support for cancer patients, with a particular focus on those who are more vulnerable.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Servier.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2008P - Brazilian real-world data of immunotherapy (IO) in extensive disease small cell lung cancer (ES-SCLC)
Presenter: Flávia Duarte
Session: Poster session 05
2009P - CNS efficacy of immune checkpoint inhibitors when combined to stereotactic radiosurgery in extensive stage small cell lung cancer
Presenter: Muhammad Awidi
Session: Poster session 05
2010P - Non-invasive radiomics signature predicts response to combination chemoimmunotherapy in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Stuthi Perimbeti
Session: Poster session 05
2011P - Machine-derived features of tumor infiltrating lymphocytes (TILs) as biomarkers of clinical outcomes to platinum chemotherapy in small cell lung cancer (SCLC)
Presenter: Prantesh Jain
Session: Poster session 05
2012P - Spatially resolved transcriptomics deciphers inter- and intra-tumor heterogeneity of small cell lung cancer
Presenter: xujie Sun
Session: Poster session 05
2013P - Investigating the clinical relevance of immune checkpoint expression in the peripheral blood of patients with small cell lung cancer (SCLC)
Presenter: Dimitrios Mavroudis
Session: Poster session 05
2014P - ATR inhibition upregulates PD-L1 and potentiates the antitumor immune response to chemoimmunotherapy in small cell lung cancer
Presenter: Triparna Sen
Session: Poster session 05
2015P - Association between gene characteristics and mutation abundance with the prognosis of small cell lung cancer
Presenter: Lian Yu
Session: Poster session 05
2016P - The role of galectin-1 in SCLC: Prognostic significance and therapeutic implications
Presenter: Arancha Cebrian
Session: Poster session 05
2017P - Comprehensive molecular profiling of small cell lung cancer patients treated with chemo-immunotherapy or chemotherapy alone
Presenter: Milena Urbini
Session: Poster session 05